Mo Jiaye, Gong Da, Zhai Mei, Yang Jintao, Li Zhike, Wu Meilong, Deng Xuesong, Dai Xiaoyong
Graduate School, Guangxi University of Chinese Medicine, Nanning 530200, Guangxi, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen 518035, Guangdong, China.
ILIVER. 2025 Jul 5;4(3):100179. doi: 10.1016/j.iliver.2025.100179. eCollection 2025 Sep.
Liver cancer is a leading cause of cancer-related death worldwide, and its complexity and heterogeneity pose considerable challenges to conventional treatment. In recent years, the rise of organoid technology has provided new perspectives and tools for precision medicine in oncology. The use of high-fidelity organoids capable of recapitulating patients' genotypic and phenotypic features can further facilitate personalised treatment. In this review, we discuss 1) the advantages of liver cancer organoids as disease models over traditional models; 2) the origin and establishment of liver cancer organoids; 3) the application of liver cancer organoids technology in tumour precision medicine; 4) the technical tools of liver cancer-derived organoids; and 5) current solutions for the deficiencies and challenges of liver cancer organoids. This review should provide both a deeper understanding of the research progress and application prospects of liver cancer organoids, as well as theoretical support and practical guidance for more complete integration of liver cancer research and precision medicine.
肝癌是全球癌症相关死亡的主要原因之一，其复杂性和异质性给传统治疗带来了巨大挑战。近年来，类器官技术的兴起为肿瘤学精准医学提供了新的视角和工具。使用能够重现患者基因型和表型特征的高保真类器官可以进一步促进个性化治疗。在本综述中，我们讨论了：1）肝癌类器官作为疾病模型相对于传统模型的优势；2）肝癌类器官的起源与建立；3）肝癌类器官技术在肿瘤精准医学中的应用；4）肝癌来源类器官的技术工具；5）当前针对肝癌类器官不足与挑战的解决方案。本综述旨在加深对肝癌类器官研究进展和应用前景的理解，为肝癌研究与精准医学更全面的整合提供理论支持和实践指导。
